Journal article
Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial
- Abstract:
-
Objectives: Oligoarticular psoriatic arthritis (PsA) is frequent but rarely studied. The objective was to assess the efficacy of apremilast in early oligoarticular PsA.
Methods: FOREMOST (NCT03747939) was a Phase 4 multicentre, randomised, double-blind, placebo-controlled trial. Patients had early (symptom duration ≤5 years) oligoarticular PsA (>1 but ≤4 swollen and >1 but ≤4 tender joints; 2-8 total active joints). Patients were randomised 2:1...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 481.1KB, Terms of use)
-
- Publisher copy:
- 10.1136/ard-2024-225833
Authors
Bibliographic Details
- Publisher:
- BMJ Publishing Group
- Journal:
- Annals of the Rheumatic Diseases More from this journal
- Publication date:
- 2024-08-20
- Acceptance date:
- 2024-07-25
- DOI:
- EISSN:
-
1468-2060
- ISSN:
-
0003-4967
Item Description
- Language:
-
English
- Keywords:
- Pubs id:
-
2018717
- Local pid:
-
pubs:2018717
- Deposit date:
-
2024-07-29
Terms of use
- Copyright holder:
- Gossec et al.
- Copyright date:
- 2024
- Rights statement:
- © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ on behalf of EULAR. http://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record